IGF1 and Renal insufficiency: Following an expert workshop between members of The Growth Hormone Research Society, the International Federation of Clinical Chemistry and Laboratory Medicine, the International Society for IGF Research and the Pituitary Society, Clemmons [120] concluded that such a set of normative data should be based on the central 95% interval of a randomly selected set of individuals across all age groups from the background population, excluding those whose medical conditions or medication, are likely to affect their IGF-1 levels (e.g., those suffering from cirrhosis, diabetes or renal failure).